BNBXOTCFinance ServicesFiscal year ends September 30
BNB PLUS CORP.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.10−0.01 (-6.67%)
Close on Oct 19, 2026
- Market cap
- $878.33K
- P/E (TTM)
- –
- Dividend yield
- –
BNB PLUS CORP. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Tagging and Security Products and Services | $1.15M | $1.22M | $1.15M | $1.57M | $1.73M | – | – | – | – | – | 53.8% | -5.7% |
| Therapeutic DNA Production Services | $988.12K | $895.35K | $1.07M | $439.36K | $559.32K | – | – | – | – | – | 46.2% | +10.4% |
| MDx Testing Services | – | $1.32M | $11.15M | $16.16M | $6.74M | – | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Tagging and Security Products and Services | -$911.14K | -$2.55M | -$3.55M | -$4.65M | -$4.82M | – | – | – | – | – | -64.3% |
| Therapeutic DNA Production Services | -$9.30M | -$4.79M | -$3.79M | -$4.50M | -$5.21M | – | – | – | – | – | +94.2% |
| MDx Testing Services | – | -$1.49M | $1.21M | -$464.89K | -$274.25K | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $1.42M | $1.07M | $1.22M | $1.88M | $3.30M | $615.43K | $2.14M | $1.83M | $3.73M | – | 66.6% | +32.5% |
| Supply chain | $1.15M | $1.21M | $827.60K | $887.06K | $1.00M | $38.58K | $1.44M | $674.22K | – | – | 53.8% | -5.0% |
| Service revenues | $712.79K | $1.04M | $996.87K | $759.14K | $937.74K | $1.24M | $3.25M | $2.08M | $1.02M | – | 33.4% | -31.4% |
| Large Scale DNA Production | $612.36K | $584.12K | $653.02K | – | – | $281.97K | $388.01K | $459.98K | – | – | 28.7% | +4.8% |
| Research and development services | $375.76K | $311.24K | $421.59K | $592.00K | $799.72K | $1.13M | $2.98M | $1.77M | – | – | 17.6% | +20.7% |
| Asset marking | – | $9.44K | $311.81K | $534.59K | $458.41K | $404.89K | $587.01K | $1.00M | – | – | – | – |
| Clinical laboratory testing services (point-in-time) | – | – | – | – | $4.79M | $77.55K | $0 | – | – | – | – | – |
| Clinical laboratory service revenues | – | $1.33M | $11.15M | $15.53M | $4.79M | $77.55K | – | – | – | – | – | – |
| Diagnostic test kits | – | – | – | – | $1.97M | – | – | – | – | – | – | – |
| Clinical laboratory testing services (over-time) | – | $1.29M | $3.54M | $5.13M | $562.50K | – | – | – | – | – | – | – |
| Clinical laboratory testing services (point-in-time) | – | $32.61K | $7.61M | $10.40M | $4.23M | – | – | – | – | – | – | – |
| MDx test kits and supplies | – | – | – | $628.29K | $1.97M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia and other | $1.02M | $989.23K | $886.44K | $175.39K | $147.89K | $499.48K | $622.40K | $757.72K | $210.44K | $131.85K | 47.8% | +3.2% |
| Americas | $1.01M | $951.90K | $12.22M | $17.54M | $8.52M | – | – | – | – | – | 47.3% | +6.2% |
| Europe | $105.58K | $172.37K | $258.36K | $448.85K | $359.51K | $266.70K | $600.37K | $1.00M | $1.06M | $876.79K | 4.9% | -38.7% |
| United States | – | – | – | – | $8.52M | $1.17M | $4.17M | $2.14M | $3.49M | $3.18M | – | – |
From the segment and revenue-disaggregation notes of Bnb Plus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.